# Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma

> **NCT02901236** · PHASE2,PHASE3 · COMPLETED · sponsor: **Athens Vision Eye Institute** · enrollment: 40 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **PROCEDURE:** Standard Guarded Trabeculectomy
- **DRUG:** Mitomycin C
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02901236
- **Lead sponsor:** Athens Vision Eye Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-01
- **Final completion:** 2016-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02901236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02901236, "Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02901236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*